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Autologous arteriovenous fistulas (AVFs) are the preferred
and recommended method for achieving vascular access for
hemodialysis in patients with end-stage renal disease.1,2
First described by Hunter in 1757, arterial dilatation after
longstanding AVF is a common finding as the artery adapts to
the increased flow rate.3,4 Late aneurysmal degeneration of
the donor arteries with the development of true aneurysms
is rare.4 True aneurysms most frequently appear in the
brachial artery but can also develop or involve other inflow
arteries.4–6 Aneurysmal degeneration is not prevented by
closure or thrombosis of the arteriovenous access and may
be associated with a history of renal transplantation and
immunosuppressive treatment.4,5
Given their rarity, complexity, and late occurrence, there
is no consensus on the management of donor brachial artery
aneurysms (DBAA).6 In this study,we analyzed the character-
istics, therapeutic options, and outcomes of true DBAA after
AVF for hemodialysis.
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Abstract True peripheral artery aneurysms proximal to a longstanding arteriovenous fistula is a
well-recognized complication. Late aneurysmal degeneration is rare. This study ana-
lyzed the characteristics, therapeutic options, and outcomes of true donor brachial
artery aneurysms (DBAA) after arteriovenous fistula (AVF) for hemodialysis. We
retrospectively collected the data of patients with DBAA after AVF creation, surgically
repaired between January 2001 and September 2015. We excluded patients with
pseudoaneurysms, anastomotic aneurysms, and infected aneurysms. We recorded
patient’s demographics, type of access, aneurysm characteristics, symptoms, treat-
ment, and follow-up. Ten patients were treated for aneurysmal degeneration of the
brachial artery. Average aneurysm diameter was 37.5 mm. All cases had, at least, one
previous distal AVF, ligated or thrombosed, at the time of diagnosis. The first access was
created in mean 137 months before the diagnosis of DBAA. Nine patients had previous
medical history of renal transplant and were under immunosuppressive therapy. All
patients were symptomatic at the time of diagnosis. In all cases, the treatment was
aneurysmectomy followed by interposition bypass. One patient developed a postop-
erative hematoma with the need of surgical drainage. At 50 months of follow-up, one
patient was submitted to percutaneous angioplasty due to an anastomotic stenosis. No
other complications occurred during the entire follow-up period (mean: 69 months).
The pathogenesis underlying DBAA remains unclear. Increased blood flow after AVF
creation, immunosuppressive therapy, and ligation/thrombosis of the AVF may
contribute to aneurysm formation. Surgical treatment by aneurysmectomy and
bypass, with autogenous conducts, is a safe and effective option.
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Methods
Aneurysm is defined as an arterial enlargement > 50% of the
normal diameter. The normal diameter for the brachial
artery is 3.5 to 4.3mm inwomen and 4.1 to 4.8mm inmen.7,8
We retrospectively reviewed the data of patients with
DBAA after AVF creation, surgically repaired at the Centro
Hospitalar do Porto – Hospital de Santo António, Porto,
Portugal, between January 2001 and September 2015.
The study excluded patients with pseudoaneurysms,
anastomotic aneurysms, and infected aneurysms. We re-
corded patient’s demographics, type of access, aneurysm
characteristics, symptoms, treatment, and follow-up.
Categorical data were described using absolute numbers
and percentages. Means ( standard deviation) andmedians
were used to analyze continuous variables.
Results
In this study, 10 patients (9 men [90%] and 1 woman [10%])
were treated for aneurysmal degeneration of the brachial
artery after AVF creation, between January 2001 and
September 2015 (►Table 1). Patients’ mean age was 52 
7.84 years (range: 37–63 years) at the time of treatment.
Nine patients (90%) had a previous history of renal trans-
plantation and were under immunosuppressive therapy.
Present cardiovascular risk factors were hypertension (90%
of patients), previous or current history of smoking (60%),
and dyslipidemia (50%). No patients had diabetes.
All cases had at least one previous distal AVF. Five patients
had 2 fistulas out of 15 fistulas in 10 patients. Patients with
two AVFs, in four cases, after thrombosis/ligation of a radio-
cephalic fistula, created a brachiocephalic fistula and in one
Table 1 Summary of treated donor brachial artery aneurysms after AVF for hemodialysis
Total number of cases 10
Mean age  standard deviation 52  7.84 y (range: 37–63)
Male 9 (90%)
Female 1 (10%)
Cardiovascular risk factors
Smoking (current/past) 6 (60%)
Diabetes 0
Hypertension 9 (90%)
Dyslipidemia 5 (50%)
Renal transplantation/immunosuppression 9 (90%)
Time to the diagnosis (since AVF creation) 136.7  60.4 mo (range: 64–288)
Mean maximum diameter 37.5  14.54 mm (range 17.5–64)
Clinical presentation
Localized pain and pulsatile mass 6 (60%)
Subacute ischemia/microembolization 3 (30%)
Acute ischemia/aneurysm thrombosis 1 (10%)
Previous ipsilateral AVFs
One 5 (50%)
Two 5 (50%)
Type of first access
Radiocephalic 6 (60%)
Brachiocephalic 4 (40%)
Adjuvant diagnostic modality
Computed tomography angiography 3 (30%)
Conventional angiography 2 (20%)
Treatment
Aneurysmectomy and GSV grafting 6 (60%)
Aneurysmectomy and basilica vein grafting 1 (10%)
Aneurysmectomy and cephalic vein grafting 2 (20%)
Aneurysmectomy and ePTFE grafting 1 (10%)
Mean follow-up 69 mo (range: 1–177)
Abbreviations: AVF, arteriovenous fistula; ePTFE, expanded polytetrafluoroethylene; GSV, great saphenous vein.
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case, after thrombosis of a brachiocephalic fistula, created a
brachiobasilic fistula. Five patients had one AVF (radioce-
phalic fistula—2 and brachiocephalic fistula—3). At the time
of diagnosis, all the previous AVFs were occluded (thrombo-
sis—4 and ligation—6).
The first access was created in mean 136.7  60.4 months
(range: 64–288 months) before the diagnosis of brachial
artery aneurysm. Location of first access was radiocephalic
in six patients and brachiocephalic in four.
All patients were symptomatic at the time of diagnosis:
localized pain and pulsatile mass—6 (60%), subacute ische-
mia/microembolization—3 (30%), and acute ischemia/aneu-
rysm thrombosis—1 (10%). Duplex scan was the primary
investigative modality in all cases. Computed tomography
(CT) scan angiography and classic angiography were used
only in selected cases. Mean aneurysm diameter was 37.5 
14.54 mm (range: 17.5–64 mm). No case presented with
multiple separate aneurysms (►Figs. 1–3).
In all cases, the treatment was aneurysmectomy followed
by interposition bypass, using great saphenous vein—6,
ipsilateral cephalic vein—2, ipsilateral basilica vein—1, or
expanded polytetrafluoroethylene—1. One patient devel-
oped a postoperative hematoma with the need of surgical
drainage. No other major complications occurred before
discharge. At 50months of follow-up, one patient underwent
percutaneous angioplasty due to an anastomotic stenosis. No
other complications occurred during the entire follow-up
period (mean: 69.2  57.67; range: 1–177 months).
Discussion
True aneurysmal degeneration of the brachial artery is rare,
with an incidence of 0.17%. Itmay be associatedwith infection,
Fig. 1 (A) Preoperative CTscan (volume rendering image); (B and C) brachial artery dissection and brachiobrachial bypass with basilica vein. CT,
computed tomography.
Fig. 2 Digital subtraction angiography showing occlusion of brachial
artery secondary to an aneurysm thrombosis.
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trauma, congenital defects, or iatrogenic injuries.6,9 Most
reported cases of true brachial artery aneurysms have been
a consequence of longstanding posttraumatic AVFs.10 Aneur-
ysms can also develop in the inflowarteries after construction
of AVFs for hemodialysis.4–6
Several studies have described an increase in the diameter
of the inflow artery after construction of an AVF in their
extremity.4–6,8,10 Arterial “growing” may be accentuated by
AVF flow and the time after fistula creation.4,8 There are four
pathophysiological steps that can explain the transition from
arteriomegaly to aneurysmal degeneration.6 First, upregula-
tion of local production of vasodilator agents (nitric oxide) and
matrix metalloproteinases 2 and 9, which results in loss of
vessel’s wall integrity and aneurysmal remodeling.11–13
Second, degradation of elastic fibers and higher amounts of
calcium and phosphate deposition (increased in dialysis
patients), with reduction in the ability of vessel’s wall to
vasoconstrict.11–14 Third, the long-term use of immunosup-
pression and corticosteroid therapy in renal transplantation
patients, that culminates in negative remodeling, due to the
activation of a proinflammatory process.15–17 Finally, in-
creased resistance of the vessel’s wall, after ligation of the
AVF, which weakens it and eventually leads to aneurysmal
dilatation.8
The prevalence of DBAA in patients with arteriovenous
accesses is difficult to determine. The rarity of these aneur-
ysms when compared with the number of AVFs created
worldwide may be explained by the limited life expectancy
of patients with end-stage renal disease undergoing hemo-
dialysis, which until recent years was not long enough to
permit the occurrence of aneurysmal degeneration.4
Donor artery aneurysms can develop from a few days to
years after AVF creation.4,5 In our series, the onset time of
brachial aneurysms varied from 64 to 288 months, with a
mean time of 136.7months. Previous reports showed similar
results.4–6
All of the brachial artery aneurysms from our series were
diagnosed after closure or thrombosis of previous ipsilateral
AVFs. Basile et al showed that vascular access closure does
not stop the development of DBAA.18 Brachial artery aneur-
ysms can appear years after AVF ligation.9,10
The most common clinical presentations of DBAA are
pain, swelling, and pulsatile mass in the arm. Distal emboli-
zation can occur in almost 30% of cases, due to mobilization
of mural thrombus within the aneurysm.4 Nerve compres-
sion/paresthesia has been described occasionally and rup-
ture is extremely rare.4,5 In our series, all patients were
symptomatic at the time of diagnosis. Our findings are in
consonance with the literature. The majority of patients
(60%) presented with localized pain and pulsatile mass,
and distal embolization occurred in 30% of the cases.
According to previous reports, duplex scan was the pri-
mary and almost the only investigative modality.6,19 CT scan
angiography, due to limitations of contrast use in renal
failure or renal transplant patients, was used only in selected
cases. We used angiography to characterize forearm runoff,
when distal embolizationwas present or when distal arteries
were involved by diffuse atherosclerotic disease.
Surgical treatment by aneurysmectomy and interposition
bypass is, in our opinion, a safe and effective option. The
results from our series are good: our patients did not develop
thrombosis of any interposition bypass, and during the
entire follow-up period, only one patient developed an
anastomotic stenosis.
Weusedautogenous conduitswhenever possible. Reported
series also prefer autogenous conducts.4–6,19 Mestres et al
defend the use of ipsilateral arm vein, when not dilated or
altered by previous AFV.19 This allows a quicker procedure
with lowermorbidityandpreserves lower limbveins for future
vascular procedures. In the present series, we also used
ipsilateral arm veins, with good results.
We think that it is important to maintain follow-up of
treated patients. There is a persistent risk of developing other
donor artery aneurysms and risk of degeneration of the
proximal and distal landing zones of the bypass. In addition,
arteriomegalymaymake itmore difficult tofind safe proximal
and distal “nonaffected” artery for anastomotic sites20.
Marzelle et al reported some cases of patients with synchro-
nous donor artery aneurysms.4
This work presents one of the largest reported series of
treated DBAA after AVF creation. Chemla et al reported treat-
ment of 13 patients with brachial artery aneurysms (6 autog-
enous interposition bypass and 7 end-to-end anastomosis;
mean follow-up of 14 months) and Martins et al reported
Fig. 3 Brachial artery aneurysm (angio-CT scan reconstruction). CT,
computed tomography.
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treatment of 6 patients (4 autogenous interposition bypass, 1
prosthetic bypass, and 1 end-to-end anastomosis; mean
follow-up of 35 months).5,21 Kordzadeh et al, in a systematic
review of donor artery aneurysms following AVF ligation,
reported 23 cases of brachial artery aneurysms.6 Our series
presents the largest number of autogenous interposition
bypass use for treatment of DBAA reported in the literature.
Our series also presents the longest mean follow-up period
(69 months).
Systematic duplex screening of donor artery aneurysms is
not defended by some authors because in most cases, aneur-
ysms can be diagnosed by physical examination.19However, it
is important to be aware of the risk of developing donor
brachial aneurysms, particularly in certain groups of patients:
patients with renal transplant or under immunosuppression
and patients with longstanding and/or high flow AVFs.
Conclusion
The pathogenesis underlying donor artery aneurysmal degen-
eration remains unclear. Increased blood flow after AVF crea-
tion, immunosuppressive therapy, and ligation/thrombosis of
the AVF may contribute to aneurysm formation.
Surgical treatment by aneurysmectomy and bypass, using
autogenous grafts, is a safe and effective option.
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